You make really good points about the raw material supplies. But, I’m curious, do you think another reason they may be rolling out the lower dose first is because they see a huge profit potential for people who have met their goals on Semaglutide and Tirzepatide wanting the lower dose oral form for long-term maintenance?
Well, with Lilly’s super aggressive orforglipron launching in the next 8-10 months, they had to do something BC orfo will eventually be **approved** for maintenance as it’s in a clinical trial for it.
You make really good points about the raw material supplies. But, I’m curious, do you think another reason they may be rolling out the lower dose first is because they see a huge profit potential for people who have met their goals on Semaglutide and Tirzepatide wanting the lower dose oral form for long-term maintenance?
Well, with Lilly’s super aggressive orforglipron launching in the next 8-10 months, they had to do something BC orfo will eventually be **approved** for maintenance as it’s in a clinical trial for it.